COAST: An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination With Oleclumab or Monalizumab in Patients With Unresectable, Stage III Non-Small-Cell Lung Cancer
MedImmune LLC
Roy S Herbst; Margarita Majem; Fabrice Barlesi; Enric Carcereny; Quincy Chu; Isabelle Monnet; Alfredo Sanchez-Hernandez; Shaker Dakhil; D Ross Camidge; Leanne Winzer; Yee Soo-Hoo; Zachary A Cooper; Rakesh Kumar; John Bothos; Charu Aggarwal; Alex Martinez-Marti